Antibody based diagnostics and therapeutics
Liselo has developed a range of antibody based diagnostics and therapeutics targeted at identified agricultural, veterinary and primary health care challenges in the developing world.
This includes the manufacture of labelled affinity-purified antibodies, used in lab-on-chip based diagnostic kits, as well as antibody based immunotherapeutic candidate drugs. Some of these therapeutic antibodies are polyclonal, others are chimeric monoclonal or multi-clonal, which are either humanised or “otherised” for extended in-vivo half life, in the affected animal.
Liselo Labs Mobile App development partner, Bengo Systems, focuses on integrating our various solutions into convenient Mobile based tools for end users and more efficient stakeholder engagement. Our telecommunications experience is leveraged to provide integrated and connected solutions, driven predominantly by mobile connectivity.
Government departments, NGO’s and researchers around the world utilise our systems to access critical data in disease and pest monitoring and management. The “Mipha” app available on Playstore and Appstore represents the worlds first “One Health” App and is linked to a nanotechnology powered molecular biology tool in the form of a range of rapid test kits.
Venomous Snake Diagnostics and Therapeutics
Liselo is currently conducting trials on a range of snake antivenom products, that promise a lower cost alternative to horse derived products, without the risk of anaphylactic complications. A rapid lab-on-chip test kit to identify which snake venom is present in an envenomed patient for Sub-Saharan venomous snakes is also in final stages of development. Simple identification of the venomous species involved with an envenomed patient, is a life saving tool.
The combination of a safe and cost effective antivenom, is a desperately needed tool particularity in Sub-Saharan Africa, where hundreds of thousands of people die annually from venomous snake bites.
Immunotherpeutic Drug Development
The team have developed a number of immunotherapeutic candidate drugs for the following diseases which are currently at various stages in the drug development cycle, with some already undergoing clinical trials:
- African Horse Sickness Virus
- Mycobacterium turberculosis
- Yellow Fever Virus
- Rabies Virus
- West Nile Virus
- Venomous snakes of Southern Africa
Research Partnerships and Collaborations
Liselo has active collaborations with the Lesotho Department of Agriculture, the North West Agriculture department in South Africa. Collaboration with academia around the world play an important role in unlocking the value of innovation in universities. Collaborations include: The Entomology Department at the University of the North West, the Centre for Nanoscale Systems (CNS) at Harvard University, Inqubate at University of Kwa-Zulu Natal, the University of Cape Town, the University of Pretoria, and the Council for Scientific and Industrial Research (CSIR).
Liselo is part of the “NuGrainSA Consortium”, which is currently co-coordinating the introduction of Quinoa to Lesotho, and the development of a pathogen free seed-bank for the SADC region. This represents a significant regional strategy to improve food security through the introduction of nutritious drought resistant crops like Quinoa.
Liselo has also partnered with the African Horse sickness trust and is building a range of tools to better manage the neglected disease. This includes a rapid test kit which is available on the market, packaged with the free Mipha App. Together with the trust Liselo is also conducting a number of field trials in 2018 on safer candidate vaccines and therapeutics.
Collaboration with universities and other research institutions around the world, has allowed the development of a test kit platform, resulting in the development of a number of rapid point-of-care diagnostics kits including:
– Arboviruses of relevance to mammalian hosts including, Yellow Fever Virus, West Nile Virus and African Horse Sickness Virus